Near-fatal asthma: Recognition and management

Current Opinion in Pulmonary Medicine

Volumn 14, Issue 1, 2008, Pages 13-23

  Restrepo, Ruben D ^a   Peters, Jay ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Asthma; Fatal asthma; Near fatal asthma; Resistant asthma

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANESTHETIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUNISOLIDE; HELIOX; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IPRATROPIUM BROMIDE; KETAMINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; LIDOCAINE; MAGNESIUM SULFATE; METHYLPREDNISOLONE; METHYLXANTHINE; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PREDNISONE; PROPOFOL; SALBUTAMOL; STEROID; TERBUTALINE; THEOPHYLLINE; UNINDEXED DRUG; VECURONIUM;

AIRWAY OBSTRUCTION; ARTIFICIAL VENTILATION; ASTHMA; ATELECTASIS; BLOOD CELL COUNT; BLOOD GAS ANALYSIS; CARDIOVASCULAR SYSTEM; CELL DAMAGE; CIGARETTE SMOKING; DISEASE EXACERBATION; DRUG MONITORING; DRUG TOLERANCE; DYSPNEA; ELECTROCARDIOGRAPHY; ELECTROLYTE BALANCE; ELECTROLYTE BLOOD LEVEL; ELECTROLYTE DISTURBANCE; EMOTIONAL STRESS; ENVIRONMENTAL FACTOR; EOSINOPHIL; EXPOSURE; FATALITY; FORCED EXPIRATORY VOLUME; GENETIC POLYMORPHISM; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEREDITY; HOSPITALIZATION; HUMAN; HYPERCAPNIA; HYPERGLYCEMIA; HYPERINFLATION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOXEMIA; IMMUNOGLOBULIN BLOOD LEVEL; LACTIC ACIDOSIS; LUNG EMPHYSEMA; LUNG FUNCTION; LYMPHOCYTIC INFILTRATION; NEAR FATAL ASTHMA; NEBULIZER; NEUTROPHIL; OXYGEN THERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICAL EXAMINATION; PNEUMOMEDIASTINUM; PNEUMONIA; PNEUMOPERICARDIUM; PNEUMORETROPERITONEUM; PNEUMOTHORAX; PROGNOSIS; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; SMOKING; SOCIAL STATUS; SPUTUM; SUBCUTANEOUS EMPHYSEMA; TACHYCARDIA; THERAPY DELAY; THORAX RADIOGRAPHY; TRACHEOESOPHAGEAL FISTULA; TREATMENT RESPONSE; VOMITING; WINTER;

ANTI-ASTHMATIC AGENTS; HOSPITALIZATION; HUMANS; MONITORING, PHYSIOLOGIC; PHENOTYPE; PROGNOSIS; RESPIRATION, ARTIFICIAL; RESPIRATORY FUNCTION TESTS; RESPIRATORY INSUFFICIENCY; RISK FACTORS; STATUS ASTHMATICUS;

EID: 36549033386     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3282f1982d     Document Type: Review

References (117)

1. McFadden ER Jr. Acute severe asthma. Am J Respir Crit Care Med 2003; 168:740-759.
2. Dhuper S, Maggiore D, Chung V, Shim C. Profile of near-fatal asthma in an inner-city hospital. Chest 2003; 124:1880-1884.
3. Molfino NA, Slutsky AS. Near fatal asthma. Eur Respir J 1994; 7:981-990.
4. Rodrigo GJ, Rodrigo C, Nannini LJ. Fatal or near-fatal asthma: clinical entity or incorrect management? Arch Bronconeumol 2004; 40:24-33.
5. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest 2004; 125:1081-1102.
6. Romagnoli M, Caramori G, Braccioni F, et al., and the ENFUMOSA Study Group. Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin Exp Allergy 2007; 37:552-557.
7. McFadden ER Jr, Warren EL. Observations on asthma mortality. Ann Intern Med 1997; 127:142-147.
8. Benatar SR. Fatal asthma. N Engl J Med 1986; 314:423-429.
9. McFadden ER Jr. Fatal and near-fatal asthma. N Engl JMed 1991; 324:409-411.
10. Molfino NA, Nannini LJ, Martelli AN, et al. Respiratory arrest in near-fatal asthma. N Engl J Med 1991; 324:285-288.
11. Rogers DF, Barnes PJ. Treatment of airway mucus hypersecretion. Ann Med 2006; 38:116-125.
12. Lopez-Vidriero MT, Reid L. Chemical markers of mucous and serum glycoproteins and their relation to viscosity in mucoid and purulent sputum from various hypersecretory diseases. Am Rev Respir Dis 1978; 117:465-477.
13. Charman J, Reid L. Sputum viscosity in chronic bronchitis, bronchiectasis, asthma and cystic fibrosis. Biorheology 1972; 9:185-199.
14. Shimura S, Sasaki T, Sasaki H, et al. Viscoelastic properties of bronchorrhoea sputum in bronchial asthmatics. Biorheology 1988; 25:173-179.
15. Sheehan JK, Richardson PS, Fung DC, et al. Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol 1995; 13:748-756.
16. Hogg JC. Pathology of asthma. J Allergy Clin Immunol 1993; 92:1-5.
17. Kuyper LM, Pare PD, Hogg JC, et al. Characterization of airway plugging in fatal asthma. Am J Med 2003; 115:6-11.
18. Rubin BK, Tomkiewicz R, Fahy JV, et al. Histopathology of fatal asthma: drowning in mucus. Pediatr Pulmonol 2001; 23:88S-89S.
19. Reid LM. The presence or absence of bronchial mucus in fatal asthma. J Allergy Clin Immunol 1987; 80:415S-419S.
20. Saetta M, Di Stefano A, Rosina C, et al. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am Rev Respir Dis 1991; 143:138-143.
21. Friedlander AL. Fatal and near-fatal asthma: phenotypes, precipitating factors, and management. Respir Rep 2007; 3:22-33.
22. Roe PF. Sudden death in asthma. Br J Dis Chest 1965; 59:158-163.
23. Wasserfallen J-B, Schaller M-D, Feihl F, et al. Sudden asphyxic asthma: a distinct entity? Am Rev Respir Dis 1990; 142:108-111.
24. Sur S, Crotty TB, Kephart GM, et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am J Respir Crit Care Med 1993; 148:713-719.
25. Rodrigo C. Acute severe asthma: management in the emergency department and in the intensive care unit [in Spanish]. Med Intensiva 2006; 30:460-470. This is an excellent review of the management of the patient with severe asthma in the emergency room and in the ICU.
26. Rodriguez-Roisin R. Acute severe asthma: pathophysiology and pathobiology of gas exchange abnormalities. Eur Respir J 1997; 10:1359-1371.
27. Rodriguez-Roisin R, Ballaster E, Roca J, et al. Mechanism of hypoxemia in patients with status asthmaticus requiring mechanical ventilation. Am Rev Respir Dis 1989; 139:732-739.
28. Papiris S, Kotanidou A, Malagari K, et al. Clinical review: severe asthma. Critical Care 2002; 6:30-44.
29. Alvarez GG, Schulzer M, Jung D, et al. A systematic review of risk factors associated with near-fatal and fatal asthma. Can Respir J 2005; 12:265-270.
30. Gelb AF, Schein A, Nussbaum E, et al. Risk factors for near-fatal asthma. Chest 2004; 126:1138-1146.
31. National Heart, Lung and Blood Institute. Guidelines for the diagnosis and management of asthma, Expert Panel Report 2. Publication no. 97-4051. Bethesda, Maryland: National Institutes of Health, 1997.
32. Turner MO, Noertjojo K, Vedal S, et al. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998; 157:1804-1809.
33. Miller MK, Johnson C, Miller DP, et al. Severity assessment in asthma: an evolving concept. J Allergy Clin Immunol 2005; 116:990-995.
34. Kikuchi Y, Okabe S, Tamura G, et al. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 1994; 330:1329-1334.
35. Rothwell RPG, Rea HH, Sears MR, et al. Lessons from the national asthma mortality study: deaths in hospital. N Z Med J 1987; 100:199-202.
36. Alvarez GG, Fitzgerald JM. A systematic review of the psychological risk factors associated with near fatal asthma or fatal asthma. Respiration 2007; 74:228-236.
37. Kolbe J, Fergusson W, Vamos M, et al. Case-control study of severe life threatening asthma (SLTA) in adults: demographics, healthcare, and management of the acute attack. Thorax 2000; 55:1007-1015.
38. Romero-Frais E, Vazquez MI, Sandez E, et al. Prescription of oral corticosteroids in near-fatal asthma patients: relationship with panic-fear, anxiety and depression. Scand J Psychol 2005; 46:459-465.
39. Nannini LJ Jr. Morbidity and mortality from acute asthma. In: Hall JB, Cordbridge TC, Rodrigo C, Rodrigo GJ, editors. Acute asthma: assessment and management. New York: McGraw Hill; 2000. pp. 10-27.
40. Magadle R, Berar-Yanay N, Weiner P. The risk of hospitalization and nearfatal and fatal asthma in relation to the perception of dyspnea. Chest 2002; 121:329-333.
41. Serrano J, Plaza V, Sureda B, et al. Alexithymia: a relevant psychological variable in near-fatal asthma. Eur Respir J 2006; 28:296-302.
42. Picado MC, Castillo JA, Monserrrat JM, et al. Aspirin-intolerance as a precipitant factor of life-threatening asthma requiring mechanical ventilation. Eur Respir J 1989; 2:127-129.
43. Yoshimine F, Hasegawa T, Suzuki E, et al. Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan. Respirology 2005; 10:477-484.
44. Levenson T, Greenberger PA, Donoghue ER, et al. Asthma deaths confounded by substance abuse: an assessment of fatal asthma. Chest 1996; 110:604-610.
45. Silverman RA, Boudreaux ED, Woodruff PG, et al. Cigarette smoking among asthmatic adults presenting to 64 emergency departments. Chest 2003; 123:1472-1479.
46. Eisner MD, Iribarren C. The influence of cigarette smoking on adult asthma outcomes. Nicotine Tob Res 2007; 9:53-56.
47. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75-80.
48. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512.
49. Huang JL. Asthma severity and genetics in Taiwan. J Microbiol Immunol Infect 2005; 38:158-163.
50. Sandford AJ, Chagani T, Zhu S, et al. Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol 2000; 106:135-140.
51. Pulleyn LJ, Newton R, Adcock IM, et al. TGFbeta1 allele association with asthma severity. Hum Genet 2001; 109:623-627.
52. Holgate ST, Yang Y, Haitchi HM, et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc Am Thorac Soc 2006; 3:440-443.
53. Holgate ST, Holloway J, Wilson S, et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006; 117:496-506. This review emphasizes the importance of recognizing different asthma phenotypes. The authors summarize some of the molecular and genetic mechanisms that explain NFA events and propose a future direction.
54. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60:1012-1018.
55. Erzurum SC. Inhibition of tumor necrosis factor alpha for refractory asthma. N Engl J Med 2006; 354:754-758.
56. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354:697-708.
57. Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006; 174:134-141. This article provides a closer look at finding the explanation for corticosteroid resistance in patients with gradual-onset NFA.
58. Corbridge TC, Hall JB. The assessment and management of adults with status asthmaticus. Am J Respir Crit Care Med 1995; 151:1296-1316.
59. Hetzel MR, Clark TJH, Branthwaite MA. Asthma: analysis of sudden deaths and ventilatory arrests in hospital. BMJ 1977; 1:808-811.
60. Lemarchand P, Labrune S, Herer B, et al. Cardiorespiratory arrest following peak expiratory flow measurement during attack of asthma. Chest 1991; 100:1168-1169.
61. Rodrigo G, Rodrigo C. Assessment of the patient with acute asthma in the emergency department. Chest 1993; 104:1325-1328.
62. Moore WC, Peters SP. Severe asthma: an overview. J Allergy Clin Immunol 2006; 117:487-494.
63. Arthur F, Gelb AF, Taylor CF, et al. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 2006; 129:1492-1499.
64. White CS, Cole RP, Lubetsky HW, et al. Acute asthma: admission chest radiography in hospitalized adult patients. Chest 1991; 100:14-16.
65. Lee YM, Park JS, Hwang JH, et al. High-resolution CT findings in patients with near-fatal asthma. Comparison of patients with mild-to-severe asthma and normal control subjects and changes in airway abnormalities following steroid treatment. Chest 2004; 126:1840-1848.
66. Grossman J. The occurrence of arrhythmias in hospitalized asthma patients. J Allergy Clin Immunol 1976; 57:310-317.
67. McFadden ER, Elsanadi N, Dixon L, et al. Protocol therapy for acute asthma: therapeutics benefits and cost savings. Am J Med 1995; 99:651-661.
68. Kelsen SG, Kelsen DP, Fleegler BF, et al. Emergency room assessment and treatment of patients with acute asthma. Am J Med 1978; 64:622-628.
69. Lin RY, Sauter D, Newman T, et al. Continuous versus intermittent albuterol nebulization in the treatment of acute asthma. Ann Emerg Med 1993; 22:1847-1853.
70. Rudnitsky GS, Eberlein RS, Schoffstall JM, et al. Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. Ann Emerg Med 1993; 22:1842-1846.
71. Rowe BH, Edmonds ML, Spooner CH, et al. Evidence-based treatments for acute asthma. Respir Care 2001; 46:1380-1390.
72. Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993; 21:1479-1486.
73. Rodrigo GJ, Rodrigo C. Continuous vs. intermittent b agonists in the treatment of acute adult asthma. A systematic review with meta-analysis. Chest 2002; 122:160-165.
74. Newhouse M. Emergency department management of life-threatening asthma: are nebulizers obsolete? Chest 1993; 103:661-663.
75. Idris AH, McDermott MF, Raucci JC, et al. Emergency department treatment of severe asthma. Metered dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. Chest 1993; 103:665-672.
76. O'Connell MB, Iber C. Continuous intravenous terbutaline infusions for adult patients with status asthmaticus. Ann Allergy 1990; 64:213-218.
77. Lawford P, Jones BMJ, Milledge JS. Comparison of intravenous and nebulised salbutamol in initial treatment of severe asthma. BMJ 1978; 1:84-85.
78. Varon J, Marik P. Managing acute severe asthma: what therapies to try, and when. J Respir Dis 2003; 24:67-76.
79. Appel D, Karpel JP, Sherman M. Epinephrine improves expiratory flow rates in patients with asthma who do not respond to inhaled metaproterenol sulfate. J Allergy Clin Immunol 1989; 84:90-98.
80. Cydulka R, Davison R, Grammer L, et al. The use of epinephrine in the treatment of older adult asthmatics. Ann Emerg Med 1988; 17:322-326.
81. Bogie AL, Towne D, Luckett PM, et al. Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. Pediatr Emerg Care 2007; 23:355-361.
82. Karpel JP, Schacter EN, Fanta C, et al. A comparison of ipratropium and albuterol vs. albuterol alone for the treatment of acute asthma. Chest 1996; 110:611-616.
83. Levy BD, Kitch B, Fanta CH. Medical and ventilatory management of status asthmaticus. Intensive Care Med 1998; 24:105-117.
84. Rodrigo GJ, Rodrigo C. First line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratoprium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000; 161:1862-1868.
85. Peters JI, Rossrucker J. Current concepts in managing status asthmaticus. J Respir Dis 1992; 13:829-849.
86. Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma. Am J Respir Crit Care Med 2001; 163:32-36.
87. Blais L, Ernst P, Boivin JF, et al. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med 1998; 158:126-132.
88. Sin DD, Tu JV. Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. Eur Respir J 2001; 17:380-385.
89. Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med 1998; 157:698-703.
90. McFadden ER Jr. Dosages of corticosteroids in asthma. Am Rev Respir Dis 1993; 147:1306-1310.
91. Rodrigo C, Rodrigo G. Treatment of acute asthma. Lack of therapeutic benefit and increase of toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer. Chest 1994; 106:1071-1076.
92. Self TH, Redmond AM, Ngyen WT. Reassessment of theophylline use for severe asthma exacerbation: is it justified in critically ill patients? J Asthma 2002; 39:677-686.
93. Aubier M, De Troyer A, Sampson M, et al. Aminophylline improves diaphragmatic contractility. N Engl J Med 1981; 305:249-252.
94. Ream RS, Loftis LL, Albers GM, et al. Efficacy of IV theophylline in children with severe status asthmaticus. Chest 2001; 119:1480-1488.
95. Rowe BH, Bretzlaff JA, Bourdon C, et al. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Issue 3. Oxford: The Cochrane Library; 2001.
96. Ho AM, Lee A, Karmakar MK, et al. Heliox vs air-oxygen mixtures for the treatment of patients with acute asthma: a systematic overview. Chest 2003; 123:882-890.
97. Rodrigo GJ, Rodrigo C, Pollack CV, et al. Use of helium-oxygen mixtures in the treatment of acute asthma: a systematic review. Chest 2003; 123:891-896.
98. Bag R, Bandi V, Fromm RE Jr, et al. The effect of heliox-driven bronchodilator aerosol therapy on pulmonary function tests in patients with asthma. J Asthma 2002; 39:659-665.
99. Kress JP, Noth I, Gehlbach BK, et al. The utility of albuterol nebulized with heliox during acute asthma exacerbations. Am J Respir Crit Care Med 2002; 165:1317-1321.
100. Camargo CA Jr, Smithline HA, Malice MP, et al. A randomized controlled trial of IV montelukast in acute asthma. Am J Respir Crit Care Med 2003; 167:528-533.
101. Silverman RA, Nowak RM, Korenblat PE. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest 2004; 126:1480-1489.
102. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant antiimmunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632-638.
103. Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of antiimmunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59:701-708.
104. Restrepo RD, Pettignano R, DeMeuse P. Halothane, an effective infrequently used drug, in the treatment of pediatric status asthmaticus: a case report. J Asthma 2005; 42:649-651.
105. Rooke GA, Choi JH, Bishop MJ. The effect of isoflurane, halothane, sevoflurane and thiopental/nitrous oxide on respiratory system resistance after tracheal intubation. Anesthesiology 1997; 86:1294-1299.
106. Burburan SM, Xisto DG, Rocco PR. Anaesthetic management in asthma. Minerva Anestesiol 2007; 73:357-365.
107. Meduri GU, Cook TR, Turner RE, et al. Noninvasive positive pressure ventilation in status asthmaticus. Chest 1996; 110:767-774.
108. Fernandez MM, Villagra A, Blanch L, et al. Noninvasive mechanical ventilation in status asthmaticus. Intensive Care Med 2001; 27:486-492.
109. Beers SL, Abramo TJ, Bracken A, et al. Bilevel positive airway pressure in the treatment of status asthmaticus in pediatrics. Am J Emerg Med 2007; 25:6-9.
110. Darioli R, Perret C. Mechanical controlled hypoventilation in status asthmaticus. Am Rev Respir Dis 1984; 129:385-387.
111. Georgopoulos D, Kondili E, Prinianakis G. How to set the ventilator in asthma. Monaldi Arch Chest Dis 2000; 55:74-83.
112. Tuxen DV. Detrimental effects of positive end-expiratory pressure during controlled mechanical ventilation of patients with severe airflow obstruction. Am Rev Respir Dis 1989; 140:5-9.
113. Guntupalli K, Bandi V. Ventilation of patients with severe obstructive lung disease. In: Dellinger R, editor. Current topics in intensive care: asthma. London: Saunders; 1996.
114. Tuxen DV. Detrimental effects of positive end-expiratory pressure during controlled mechanical ventilation of patients with severe airflow obstruction. Am Rev Respir Dis 1989; 140:5-10.
115. American Lung Association Epidemiology and Statistics Unit, Research and Program Services. Trends in asthma morbidity and mortality. http://www.lungusa. org/atf/cf/%7B7A8D42C2-FCCA-4604-8ADE-7F5D5E762256% 7D/TREND_ASTHMA2007.pdf. 2007.
116. Mutch WA, Buchman TG, Girling LG, et al. Biologically variable ventilation improves gas exchange and respiratory mechanics in a model of severe bronchospasm. Crit Care Med 2007; 35:1749-1755.
117. Bellido J, Plaza V, Bargadi S, et al. Is the incidence of near-fatal asthma decreasing in spain? Arch Bronchoneumol 2006; 42:522-525.